Cargando…

Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications

Renal cell carcinoma (RCC) comprises a diverse group of malignancies arising from the nephron. The most prevalent type, clear cell renal cell carcinoma (ccRCC), is characterized by genetic mutations in factors governing the hypoxia signaling pathway, resulting in metabolic dysregulation, heightened...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolf, Melissa M., Rathmell, W. Kimryn, Beckermann, Kathryn E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194123/ https://www.ncbi.nlm.nih.gov/pubmed/32123314 http://dx.doi.org/10.1038/s41388-020-1234-3

Ejemplares similares

Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
por: Ghatalia, Pooja, et al.
Publicado: (2018)

Renal cell carcinoma
por: Jonasch, Eric, et al.
Publicado: (2014)

Emerging Targets in Clear Cell Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies
por: Rathmell, Kimryn W., et al.
Publicado: (2015)

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017)

The therapeutic implications of immunosuppressive tumor aerobic glycolysis
por: Reinfeld, Bradley I., et al.
Publicado: (2021)

Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy
por: Rojas, Juan D., et al.
Publicado: (2018)

Racial difference in histologic subtype of renal cell carcinoma
por: Olshan, Andrew F, et al.
Publicado: (2013)

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma
por: Wood, Christopher G., et al.
Publicado: (2020)

HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells
por: Arreola, Alexandra, et al.
Publicado: (2014)

Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell–Renal-Cell-Carcinoma: Proof-of-Concept Study
por: Yin, Qingbo, et al.
Publicado: (2017)

The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
por: Lim, Aaron R, et al.
Publicado: (2020)

Editorial: Case reports in renal cell carcinoma
por: Zhuang, Tony Z., et al.
Publicado: (2023)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2021)

Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma
por: Ahluwalia, Pankaj, et al.
Publicado: (2021)

A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma
por: Nakajima, Erica, et al.
Publicado: (2017)

CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
por: Beckermann, Kathryn E., et al.
Publicado: (2020)

Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
por: Lee, Cheol, et al.
Publicado: (2017)

VHL Type 2B Mutations Retain VBC Complex Form and Function
por: Hacker, Kathryn E., et al.
Publicado: (2008)

Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications
por: Wang, Yongfeng, et al.
Publicado: (2021)

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
por: Liu, Xian-De, et al.
Publicado: (2020)

Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma
por: Murakami, A, et al.
Publicado: (2017)

Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy
por: Chen, Ronghui, et al.
Publicado: (2023)

Renal Clear Cell Carcinoma and Tonsil Metastasis
por: Marcotullio, Dario, et al.
Publicado: (2013)

ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
por: Seidel, Philipp, et al.
Publicado: (2022)

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
por: Chen, Yu-Wei, et al.
Publicado: (2022)

Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma
por: Xu, Wen-Hao, et al.
Publicado: (2019)

Clinical Implications of HSC70 Expression in Clear Cell Renal Cell Carcinoma
por: Zhang, Yixiao, et al.
Publicado: (2021)

Integrative computational immunogenomic profiling of cortisol‐secreting adrenocortical carcinoma
por: Baechle, Jordan J., et al.
Publicado: (2021)

Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications
por: Wang, Qiang, et al.
Publicado: (2021)

Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma
por: Wang, Yi, et al.
Publicado: (2022)

The role and therapeutic significance of the anoikis pathway in renal clear cell carcinoma
por: Wang, Jin, et al.
Publicado: (2022)

Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma
por: Hou, Weibin, et al.
Publicado: (2018)

Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma
por: Liu, Huiqing, et al.
Publicado: (2010)

Role of NF-κB pathway in kidney renal clear cell carcinoma and its potential therapeutic implications
por: Sun, Jiaao, et al.
Publicado: (2023)

Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
por: Haake, Scott, et al.
Publicado: (2023)

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma
por: Chipollini, Juan, et al.
Publicado: (2018)

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K., et al.
Publicado: (2022)

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
por: Shiuan, Eileen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ehag09l7pluufgj4oe14o1dsut